July 15, 2022
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022 Positioning Pharma and Diagnostics for post-COVID recovery and growth in 2022 and beyond Reaffirms FY 2022 guidance of 15-20% revenue growth CAMBRIDGE, Mass.
Displaying 1 - 10 of 21